tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Hookipa Pharma (HOOK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOCResearch Report) and Hookipa Pharma (HOOKResearch Report).

Teladoc (TDOC)

SVB Securities analyst Stephanie Davis maintained a Hold rating on Teladoc on July 20 and set a price target of $2.00. The company’s shares closed last Friday at $41.18, close to its 52-week low of $27.38.

According to TipRanks.com, Davis is a 1-star analyst with an average return of -1.5% and a 48.5% success rate. Davis covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and Change Healthcare.

Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $42.29, a -3.4% downside from current levels. In a report issued on July 11, Bank of America Securities also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

Hookipa Pharma (HOOK)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Hookipa Pharma on July 20 and set a price target of $9.00. The company’s shares closed last Friday at $1.57, close to its 52-week low of $1.25.

According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 0.8% and a 48.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

Hookipa Pharma has an analyst consensus of Strong Buy, with a price target consensus of $6.33, a 279.0% upside from current levels. In a report issued on July 20, JMP Securities also reiterated a Buy rating on the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TDOC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More